A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Refractory or Relapsed Lymphoid Malignancies

NCT02175433 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

71

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed Lymphoid Malignancy
Refractory Lymphoid Malignancy

Interventions

DRUG: AGS67E

Sponsor

Astellas Pharma Global Development, Inc.